AMLX

Amylyx Pharmaceuticals, Inc. (AMLX) - Q2 2026 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended June 30, 2026. Amylyx is a clinical-stage pharmaceutical company focused on developing novel therapies for endocrine conditions and neurodegenerative diseases. The company's primary pipeline includes avexitide (for post-bariatric hypoglycemia), AMX0035 (for Wolfram syndrome), AMX0114 (for ALS), and AMX0318 (for PBH and other rare diseases). The company has no current product revenue and relies on cash reserves and financing to fund operations.

Key Financial Metrics

Material Changes vs. Prior Period

• Operating Expenses: Total operating expenses increased by 7% in Q2 2026 compared to Q2 2025. This was driven by a 40% increase in Selling, General, and Administrative (SG&A) expenses, primarily due to legal fees related to the settlement of the Shih class action lawsuit and increased pre-commercialization marketing activities. Research and Development (R&D) expenses decreased by 13% in Q2, largely due to the discontinuation of the AMX0035 program for Progressive Supranuclear Palsy (PSP), which was partially offset by increased spending on the pivotal Phase 3 LUCIDITY trial for avexitide.
• Net Loss: Net loss increased slightly by 5% in Q2 2026 ($43.4M vs $41.4M) and by 10% on a year-to-date basis ($84.7M vs $77.4M).
• Liquidity: Total cash, cash equivalents, and marketable securities decreased from $317.0 million at December 31, 2025, to $250.8 million at June 30, 2026. This reduction reflects operating cash burn and net investing outflows, including a $4.0 million milestone payment to Gubra A/S for the AMX0318 program.
• Legal Settlement: The company reached an agreement in principle to settle the Shih class action lawsuit for $6.5 million, a significant portion of which is funded by insurance. The court preliminarily approved the settlement in May 2026.

Guidance, Outlook, and Risks

• Cash Runway: Management believes existing cash and marketable securities ($250.8 million) are sufficient to fund operations into 2028.
• Clinical Milestones:
  • Avexitide (PBH): The Phase 3 LUCIDITY trial has completed dosing. Topline data is expected in Q3 2026. A commercial launch is targeted for 2027 if approved.
  • AMX0035 (Wolfram Syndrome): Long-term data (Week 96) from the HELIOS trial showed sustained improvement or stabilization in pancreatic function and glycemic control. The company is working with the FDA on a Phase 3 trial design.
  • AMX0114 (ALS): The Phase 1 LUMINA trial is ongoing. Cohorts 1 and 2 are fully enrolled; Cohort 3 is enrolling. Biomarker data presented in June 2026 showed no drug-related serious adverse events.
  • AMX0318: Selected as a development candidate in January 2026. IND-enabling studies are underway with a submission targeted for 2027.
  • Risks:
    • Capital Needs: The company expects to continue generating significant losses and may require additional funding before 2028 if clinical timelines extend or costs increase.
    • Regulatory Uncertainty: Success depends on the outcome of the LUCIDITY trial and FDA approval pathways. The company faces risks related to the "combination rule" for AMX0035.
    • Legal Proceedings: In addition to the settled Shih case, derivative complaints are pending. While settlement negotiations are ongoing, the outcome remains uncertain.
    • Reporting Status: The company will cease to qualify as a "smaller reporting company" effective January 1, 2027, which will increase compliance costs and disclosure requirements.

  Investor Verification Checklist

  • Verify the Q3 2026 topline data announcement for the avexitide LUCIDITY Phase 3 trial, as this is the primary catalyst for near-term valuation.
  • Confirm the final court approval of the $6.5 million settlement for the Shih class action lawsuit and the extent of insurance coverage.
  • Monitor the cash burn rate and any announcements regarding additional equity or debt financing needs prior to the projected 2028 runway.
  • Review the FDA's feedback on the Phase 3 trial design for AMX0035 in Wolfram syndrome, particularly regarding the fixed-dose combination requirements.
  • Assess the impact of the upcoming transition to non-smaller reporting company status in 2027 on future operating expenses.